EBITDA: Income before interest, taxes, depreciation and amortization.
Cognition Therapeutics, Inc. (CGTX) had EBITDA of $-47.57M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-23.49M |
|
-- |
|
-- |
|
$47.80M |
|
$-47.80M |
|
$24.31M |
|
$-23.49M |
|
$-23.49M |
|
$-23.49M |
|
$-23.49M |
|
$-23.49M |
|
$-23.49M |
|
$-47.80M |
|
|
EBITDA |
$-47.57M |
72.77M |
|
72.77M |
|
$-0.32 |
|
$-0.32 |
|
| Balance Sheet Financials | |
$47.99M |
|
$0.09M |
|
$0.40M |
|
$48.39M |
|
$13.92M |
|
-- |
|
$0.20M |
|
$14.12M |
|
$34.27M |
|
$34.27M |
|
$34.27M |
|
88.90M |
|
| Cash Flow Statement Financials | |
$-24.59M |
|
$0.01M |
|
$36.57M |
|
$25.01M |
|
$37.00M |
|
$11.99M |
|
$2.09M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.45 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-24.58M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-68.53% |
|
-68.53% |
|
-48.54% |
|
-68.53% |
|
$0.39 |
|
$-0.34 |
|
$-0.34 |
|